Human Trials

Inovio’s HIV vaccine succeeds in early stage trial

Inovio Pharmaceuticals' Pennvax-GP HIV vaccine has demonstrated nearly 100% immune response rates in a clinical study.

Inovio’s HIV vaccine combination Pennvax-GP succeeds in early stage trial

Inovio Pharmaceuticals has reported that its Pennvax-GP HIV vaccine combination has succeeded in an early stage clinical trial by evoking nearly 100% immune response rates in participants.

Shire’s swelling disorder drug meets primary and secondary endpoints in phase 3 study

Shire’s swelling disorder treatment, lanadelumab, has met its primary endpoint and all secondary endpoints in a phase 3 study.

ImmunoGen unveils promising data with mirvetuximab soravtansine in ovarian cancer

ImmunoGen has reported promising safety and efficacy data from monotherapy and combination trials with mirvetuximab soravtansine in patients with folate receptor alpha (FRα)-positive epithelial ovarian cancer (EOC).

Ardelyx reports positive results from phase 3 trial of Tenapanor in IBS-C patients

Ardelyx reported positive, topline results from the T3MPO-1 trial, the first of two Phase 3 trials evaluating tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).

Lilly’s migraine drug galcanezumab succeeds in three phase 3 studies

Eli Lilly's galcanezumab has met its primary endpoint in three phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) showing statistically significant reductions in the number of monthly migraine headache days against placebo at both studied doses.

Roche’s advanced bladder cancer drug Tecentriq fails in phase 3 trial

Roche’s phase III IMvigor211 study of Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed during or after treatment with a platinum-based chemotherapy (previously treated) has failed to meet its primary endpoint of overall survival (OS) compared to chemotherapy.

Daiichi Sankyo initiates phase 3b study of Lixiana

Daiichi Sankyo announced the initiation of the ENVISAGE-TAVI AF study of Lixiana by enrolling the first patient in the trial.

Myovant’s hormonal therapy relugolix succeeds in phase 2 trial

Myovant Sciences has reported positive results from a placebo-controlled Phase 2 dose-finding trial evaluating the ability of relugolix to decrease heavy menstrual bleeding in women with uterine fibroids which was conducted by Takeda Pharmaceutical in Japan.